[P01] Poster 1 (5. Vaccine / Odd Number)

[P109] Low-inflammatory lipid nanoparticle-based mRNA vaccine elicits superior protective immunity against H5N1 high-pathogenicity avian influenza virus with reduced adverse reactions

Taro Shimizu^1,2,3, Hiroki Tanaka^3,4, Shintaro Shichinohe⁵, Toshiro Hirai^1,2,3,6, Tokiko Watanabe^3,5,7, Hidetaka Akita^3,4, ○Yasuo Yoshioka^1,2,3,6,7,8 (1. Vaccine Creation Group, Research Institute for Microbial Diseases, Osaka University (Japan), 2. OTRI, Osaka University (Japan), 3. CAMaD, Osaka University (Japan), 4. Graduate School of Pharmaceutical Sciences, Tohoku University (Japan), 5. Department of Molecular Virology, Research Institute for Microbial Diseases, Osaka University (Japan), 6. Graduate School of Pharmaceutical Sciences, Osaka University (Japan), 7. CiDER, Osaka University (Japan), 8. The Research Foundation for Microbial Diseases of Osaka University (Japan))

閲覧にはパスワードが必要です